Researchers at Baylor College of Medicine and Columbia University found that almost all blood samples from pregnant women tested contained several trophoblasts.
The team will present the results to the US Food and Drug Administration as part of a 510(k) application in order to commercialize the technology with Biofluidica.
The study, presented at the American Society of Hematology meeting, also suggested that a moleculary guided strategy may lead to better outcomes than standard of care.
While NanoString will commercialize its nCounter for research use applications, Veracyte will move its current assays onto the platform to reach a global audience.
The database of proteins secreted into blood provides a resource for basic research as well as a potential list of targets for drug and diagnostics development.
In a preprint posted on BioRxiv this week, Decode researchers used nanopore sequencing to characterize structural variants in more than 1,800 Icelandic individuals.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
Findings of a new study point to the need for technological solutions and education to improve local healthcare providers' ability to discuss genetic information with patients.
Following its departure from the European Union, the UK is to implement a fast-track visa program aimed at attracting scientific talent to Britain, according to BBC News.
ScienceInsider reports that researchers in Brazil are concerned that a creationist was chosen to run the agency that oversees graduate study programs there.
In PLOS this week: common variant associated with BMI in Arctic populations, analysis of microRNA markers associated with being born small for gestational age, and more.
